The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1416
Canagliflozin (Invokana) for Type 2 Diabetes
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

Canagliflozin (kan" a gli floe' zin; Invokana – Janssen), a sodium-glucose co-transporter 2 (SGLT2) inhibitor, has been approved by the FDA for oral treatment of type 2 diabetes.

DRUGS FOR DIABETES — Lifestyle modifications and metformin (Glucophage, and others) should be used first to treat patients with type 2 diabetes. If metformin alone fails to control hyperglycemia, there is no general agreement on which drug should be added next. Some available agents and their advantages and disadvantages are listed in Table 1. Many of these drugs are available in fixed-dose combinations with metformin. Most patients with type 2 diabetes eventually require multidrug therapy or insulin.1

SGLT2 INHIBITORS — Canagliflozin is the first SGLT2 inhibitor marketed in the US. ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Canagliflozin (Invokana) for Type 2 Diabetes
Article code: 1416a
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian